DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,074 filers reported holding DANAHER CORPORATION in Q4 2022. The put-call ratio across all filers is 1.10 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $396,144 | -4.9% | 1,572 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $416,580 | +2.6% | 1,572 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $406,000 | -73.6% | 1,572 | -74.0% | 0.00% | -77.8% |
| Q2 2022 | $1,535,000 | -23.1% | 6,043 | -11.3% | 0.01% | +125.0% |
| Q1 2022 | $1,996,000 | -12.2% | 6,811 | -1.5% | 0.00% | -33.3% |
| Q4 2021 | $2,274,000 | -93.8% | 6,912 | -94.3% | 0.01% | -93.2% |
| Q3 2021 | $36,897,000 | +2.2% | 121,373 | -9.9% | 0.09% | -1.1% |
| Q2 2021 | $36,107,000 | +1959.7% | 134,726 | +1629.7% | 0.09% | +1383.3% |
| Q1 2021 | $1,753,000 | -37.0% | 7,789 | -37.9% | 0.01% | -64.7% |
| Q4 2020 | $2,782,000 | +107.1% | 12,533 | +100.6% | 0.02% | +30.8% |
| Q3 2020 | $1,343,000 | -4.2% | 6,248 | -21.1% | 0.01% | -13.3% |
| Q2 2020 | $1,402,000 | +23.3% | 7,921 | -3.8% | 0.02% | +7.1% |
| Q1 2020 | $1,137,000 | -39.2% | 8,238 | -32.6% | 0.01% | -17.6% |
| Q4 2019 | $1,870,000 | – | 12,219 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |